Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Holdings Increased by Amalgamated Bank

Amalgamated Bank lifted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 60.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,357 shares of the company’s stock after acquiring an additional 513 shares during the quarter. Amalgamated Bank’s holdings in Mirum Pharmaceuticals were worth $46,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. William Blair Investment Management LLC increased its stake in shares of Mirum Pharmaceuticals by 8.1% in the second quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock valued at $23,179,000 after purchasing an additional 50,667 shares during the period. Ground Swell Capital LLC acquired a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at approximately $369,000. Rice Hall James & Associates LLC grew its stake in shares of Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after purchasing an additional 14,843 shares in the last quarter. Quest Partners LLC increased its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after acquiring an additional 1,127 shares during the period. Finally, Candriam S.C.A. acquired a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $17,384,000.

Mirum Pharmaceuticals Trading Up 2.9 %

NASDAQ:MIRM opened at $40.12 on Wednesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $45.23. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The business has a 50 day moving average price of $40.80 and a two-hundred day moving average price of $32.64. The company has a market cap of $1.89 billion, a P/E ratio of -10.81 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The firm had revenue of $77.90 million during the quarter, compared to the consensus estimate of $75.03 million. Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The business’s revenue was up 107.7% on a year-over-year basis. During the same period last year, the business earned ($0.92) EPS. As a group, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MIRM shares. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Friday, July 26th. Citigroup raised their price target on Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th. Cantor Fitzgerald lifted their price target on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price target on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, June 18th. Finally, Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $56.27.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.